Gilead Sciences Inc $91.46

up +1.62


28/7/2014 04:00 PM  |  NASDAQ : GILD  
Industries : Drugs / Biotechnology
Get Trend Analysis Icon Get GILD Trend Analysis - it has outperformed the S&P 500 by 29%

Partner Headlines

  1. #PreMarket Primer: Monday, July 28: Tension Between U.S. And Israel On ...

    Benzinga
  2. Creating Cures And Dividends Where None Existed Before With Gilead Sciences

    GuruFocus
  3. Q2 Revenue Best Since 2012

    IBD
  4. Q2 Revenue Strongest Since 2012 As Recovery Quickens

    IBD
  5. AbbVie Beats Earnings Views, Sees Slower Humira Gain

    IBD
  6. Celgene, Alexion Beat Estimates, But Biotechs Fall

    IBD
  7. Celgene, Alexion Earnings Top Street, But Stocks Fall

    IBD
  8. Gilead Beats Q2 Views On Revenue Growth Lead By Sovaldi Drug

    Benzinga
  9. Biogen, Gilead Profits Soar

    IBD
  10. Biogen, Gilead Crush Earnings Estimates On Hot Drugs

    IBD
  11. Markets Mostly Higher As Earnings Season Continues To Impress

    Benzinga
  12. IPO Stock Watch: Biotechs Are Half Of July Calendar

    IBD
  13. Biogen Trounces Q2 Estimates As Tecfidera Outperforms

    IBD
  14. Statement from FDA Confirms Approval of Gilead's Zydelig

    Benzinga
  15. Earnings Scheduled For July 23, 2014

    Benzinga
  16. Alexion, 3 Other Top Biotechs Reporting Earnings

    IBD
  17. Biogen Shares Rebound As Street Has A Change Of Heart

    IBD
  18. Facebook, Gilead Headline IBD 50's Top 5 Earnings

    IBD
  19. Investors Focus On Earnings Rather Than Geopolitical Tensions

    Benzinga
  20. Biotech Enters Reporting Season With Large Caps Central To Sector Performance

    Benzinga
  21. Stocks Up In Late Trade; AerCap Nears Resistance

    IBD
  22. Stocks Add To Gains; Under Armour Rebounds

    IBD
  23. Yellen Swats Down Biotech, Social Media Stocks

    FoxBusiness
  24. J&J Earnings Beat Estimates, But Guidance Mixed

    IBD
  25. Economic News Today: Yellen Says Some Stock Valuations 'Stretched'

    IBD
  26. Biogen's Profit Rolls Amid Recent Drug Launches

    IBD
  27. Senate grills Gilead on price

    IBD
  28. Stocks Mixed In Low-Volume Session; Facebook Firms Up

    IBD
  29. Senators Ask Gilead To Explain Sovaldi Pricing

    IBD
  30. Stocks Hitting 52-Week Highs

    Benzinga
  31. J.P. Morgan: Johnson & Johnson's Drug Segment May Beat Q2 Street Views

    Benzinga
  32. Alexion Pharma Looks To Life Beyond Its Blockbuster

    IBD
  33. Japan approves BMY regimen

    IBD
  34. Warmer Weather Improving Q2 Earnings Forecasts

    IBD
  35. Biotech Stocks Gilead, Anika Still Near Buy Points

    IBD
  36. Bristol-Myers' All-Oral HCV Therapy Approved In Japan

    IBD
  37. Weekly CEO Sells Highlight: Karopharm Therapeuticcs Inc., Methode Electronics ...

    GuruFocus
  38. IBD 50: Salix, Gilead Among Top Expected EPS Gainers

    IBD
  39. Salix, Jazz Lead As Drugmakers Pace IBD 50 For Week

    IBD
  40. IBD 50: New Drug Driving Gilead's Sales, Earnings

    IBD
  41. Merck, Gilead Lead Race To Eradicate Hepatitis C

    IBD
  42. Citi Sees Plenty Of Q2 Earnings Beats Ahead In Biotech Sector

    Benzinga
  43. Stocks Nearly Flat In Quiet Trading With 1 Hour To Go

    IBD
  44. Stocks Edge Higher In Soft Trade; Ambarella Adds To Gains

    IBD
  45. Stocks Up Slightly In Choppy Trade; BitAuto Rallies

    IBD
  46. UPDATE: Morgan Stanley Reiterates On Gilead Sciences On EM Sovaldi

    Benzinga
  47. Stocks Finish Higher; GoPro Extends IPO Advance

    IBD
  48. Bristol-Myers, Pfizer, Regeneron Drugs Get EU Nods

    IBD
  49. Vertex Cystic Fibrosis Success Quells Street's Doubts

    IBD
  50. Weekly CFO Sells Highlight: Facebook Inc, Workday Inc, Gilead Sciences ...

    GuruFocus
Trading Center